Global Pharmacokinetic Testing Market Growth (Status and Outlook) 2025-2031
The global Pharmacokinetic Testing market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.
Market drivers include:
- Increasing demand for healthcare
- Technological advancements
- Rising prevalence of chronic diseases
- Increase in funding from private & government organizations for development of pharmaceutical manufacturing segments
- Rise in R&D activities for drugs
However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations.
This report looks at past sales and reviews total world Pharmacokinetic Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected Pharmacokinetic Testing sales for 2025 through 2031.
Segmentation by Type:
- Oral Dissolution Testing (FDC)
- Intravenous Titration Test (IVRT)
- Cell Line In-house Testing (ICR)
Segmentation by Application:
- Hospital
- Clinic
- Research Institutions
This report also splits the market by region:
- Americas
- APAC
- Europe
- Middle East & Africa
Companies coverage:
- Pharmaceutical Product Development, LLC
- Charles River Laboratories International, Inc.
- Creative Bioarray
- Certara, L.P.
- Evotec AG
- Pacific BioLabs
- GVK Biosciences Private Limited
- SGS SA
- LGC Limited
Key Questions Addressed in this Report:
Frequently Asked Questions
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market